Oncurious’ first project, TB-403, is a therapeutic antibody being studied for the treatment of amongst others medulloblastoma , a rare, life-threatening brain tumor that mainly affects children.
With treatment, around 60-65% of children with high-risk medulloblastoma, and 80-90% of those with disease that has not spread, can be expected to be free of disease 5 years later. However, in 20-40% of children the disease comes back (relapses) and in children who relapse 3-year survival rates after relapse have been estimated to be as low as 19%.
The risk for relapse and the significant long-term neurocognitive impairment associated with current treatment modalities, underscore the urgent need for novel tumor-specific therapies, such as TB-403.
The safety of TB-403 has been previously studied in 70 adult cancer patients. These studies showed that TB-403 was well tolerated.
Phase I/IIa study
The study has been initiated and follows the earlier announced partnership between Oncurious, its TB-403 project partner BioInvent, and the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) in the US. NMTRC is a collaboration of 25 US academic medical centers, teaching hospitals and other entities, with the purpose of facilitating and conducting collaborative research activities and investigations of new treatments for neuroblastoma, medulloblastoma and other pediatric cancers.
Headquartered at the Helen DeVos Children’s Hospital in Grand Rapids, MI, USA, NMTRC is the key clinical trial partner for this Phase I/IIa study. The study aims at recruiting a minimum of 27 patients, with first results expected to be reported in 2017.
Children responding to TB-403 will have the opportunity to continue treatment.
Keep an eye on our news page for updates on the progress being made.
|Phase I/IIa First patient in planned for Q1 2016|